deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03047928

Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma

Sponsor: Inge Marie Svane

Conditions Metastatic Melanoma
Interventions Nivolumab PD-L1/IDO peptide vaccine
Updated 13 times since 2017 Last updated: Feb 1, 2025 Started: Feb 22, 2018 Primary completion: Dec 31, 2022 Completion: Dec 31, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Metastatic Melanoma and is currently completed. Inge Marie Svane leads this study, which shows 13 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Feb 2017 – ~Feb 2018 · 12 months · monthly snapshot~Feb 2018 – ~Mar 2018 · 28 days · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Sep 2020 · 22 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Apr 2022 · 15 months · monthly snapshot~Apr 2022 – ~Sep 2022 · 5 months · monthly snapshot~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Mar 2025 · 5 months · monthly snapshot~Mar 2025 – present · 16 months · monthly snapshot

Change History

13 versions recorded

  1. Mar 2025 — Present [monthly]

    Completed PHASE1/PHASE2

    Status: Unknown → Completed

  2. Oct 2024 — Mar 2025 [monthly]

    Unknown PHASE1/PHASE2

    Status: Recruiting → Unknown

  3. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE1/PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  5. Sep 2022 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 8 earlier versions

  1. Apr 2022 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

  2. Jan 2021 — Apr 2022 [monthly]

    Recruiting PHASE1_PHASE2

  3. Sep 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  4. Nov 2018 — Sep 2020 [monthly]

    Recruiting PHASE1_PHASE2

  5. Jun 2018 — Nov 2018 [monthly]

    Recruiting PHASE1_PHASE2

  6. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  7. Feb 2018 — Mar 2018 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  8. Feb 2017 — Feb 2018 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Inge Marie Svane
Data source: Herlev Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations